Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
In this medfyle
The final analysis of the ALPINE trial, with a median follow-up of 42.5 months, confirmed the sustained superiority of zanubrutinib over ibrutinib in patients with RR CLL/SLL. Zanubrutinib demonstrated a significant PFS benefit, including in high-risk patients with del(17p)/TP53 mutations. Safety analysis highlighted fewer cardiac events and a lower incidence of atrial fibrillation/flutter with zanubrutinib, alongside a stable or decreasing prevalence of adverse events year-over-year. Based on these data, zanubrutinib offers superior efficacy and a more favorable safety profile than ibrutinib.
About this Medfyle
©2025 Medfyle. All rights reserved.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, American Society of Hematology's official journal.
Original article: Brown JR, Eichhorst B, Lamanna N, O'Brien SM, Tam CS, Qiu L, Jurczak W, Zhou K, Šimkovič M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang M, Salmi T, Wang L, Li J, Wu K, Cohen A, Shadman M. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26;144(26):2706-2717.
